Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2023 Apr 18;12(3):152-155.
doi: 10.1093/jpids/piac124.

Monoclonal Antibody Use for Coronavirus Disease 2019 in Pediatric Patients: A Multicenter Retrospective Study

Gilad Sherman  1   2 , Gabriella S Lamb  1   2 , Tanvi S Sharma  1   2 , Elizabeth C Lloyd  3 , Jerod Nagel  4 , Nada N Dandam  4 , Carlos R Oliveira  5 , Hassan S Sheikha  5 , Brenda I Anosike  6 , Philip Lee  6 , Surabhi B Vora  7 , Karisma Patel  8 , Paul K Sue  8 , Beenish Rubbab  8 , April M Yarbrough  9 , Lakshmi Ganapathi  1   2 , Mari M Nakamura  1   2   10
Affiliations
Multicenter Study

Monoclonal Antibody Use for Coronavirus Disease 2019 in Pediatric Patients: A Multicenter Retrospective Study

Gilad Sherman et al. J Pediatric Infect Dis Soc. .

Abstract

Monoclonal antibodies for COVID-19 are authorized in high-risk patients aged ≥12 years, but evidence in pediatric patients is limited. In our cohort of 142 patients treated at seven pediatric hospitals between 12/1/20 and 7/31/21, 9% developed adverse events, 6% were admitted for COVID-19 within 30 days, and none received ventilatory support or died.

Keywords: COVID-19; SARS-CoV-2; bamlanivimab and etesevimab; casirivimab and imdevimab; monoclonal antibodies; pediatric.

PubMed Disclaimer

Comment in

References

    1. Centers for Disease Control and Prevention. COVID Data Tracker. 2022. https://covid.cdc.gov/covid-data-tracker. Accessed November 11, 2022.
    1. American Academy of Pediatrics. Management Strategies in Children and Adolescents with Mild to Moderate Covid-19. 2022. http://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/c.... Accessed August 22, 2022.
    1. Centers for Medicare & Medicaid Services. COVID-19 Monoclonal Antibodies | CMS. 2022. https://www.cms.gov/monoclonal. Accessed August 22, 2022. - PubMed
    1. Chen P, Nirula A, Heller B, et al. . SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N Engl J Med 2021; 384:229–237. doi: 10.1056/NEJMoa2029849 - DOI - PMC - PubMed
    1. Dougan M, Nirula A, Azizad M, et al. . Bamlanivimab plus etesevimab in mild or moderate Covid-19. N Engl J Med 2021; 385:1382–1392. doi: 10.1056/NEJMoa2102685 - DOI - PMC - PubMed

Publication types

Substances